New Developments in Pharmacological Treatment of Obesity and Type 2 DiabetesBeyond and within GLP 1 Receptor Agonists CAGRILINTIDE PEPTIDE 5MG 10MG VIAL UMBRELLA Labs New trial data on CagriSema 23% weight loss at 84 weeks in the RE DEFINE 4 trial. CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Amylin is a pancreatic hormone that slows PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Triple Agonism Based Therapies for Obesity Current Cardiovascular Risk Reports Springer Nature Link